Making the Most of ADCs: Balancing Benefits and Managing Concerns in Ovarian Cancer
**Sequencing and Patient Readiness for ADC Therapy:** Panelists discuss how ADC therapy approval has reshaped ovarian cancer treatment sequencing by prioritizing these agents over traditional regimens in platinum-resistant patients with high folate receptor alpha expression, while emphasizing the critical need for patient education about unpredictable novel side effects and continuous monitoring based on patient-reported symptoms.
EP: 1.Managing Recurrent Ovarian Cancer: Tailoring Approaches Based on Platinum Sensitivity
EP: 2.The Role of Molecular Testing in Ovarian Cancer Care
EP: 3.From Challenges to Solutions: Ensuring Timely and Effective Molecular Testing in Ovarian Cancer
EP: 4.Mirvetuximab Soravtansine in Ovarian Cancer: Clinical Perspectives and Key Insights from MIRASOL
EP: 5.Advances in ADC Therapy for Ovarian Cancer
EP: 6.Making the Most of ADCs: Balancing Benefits and Managing Concerns in Ovarian Cancer
Sequencing and Patient Readiness for ADC Therapy
The approval of ADC therapy has reshaped treatment sequencing in ovarian cancer. In platinum-resistant settings, high folate receptor alpha expression often warrants prioritization of ADCs over older regimens like bevacizumab doublets. Strong clinical responses support earlier use of these agents for eligible patients.
When initiating ADC therapy, the primary concern is patient education about novel side effects, especially those differing from traditional chemotherapy. Patients need to be prepared for symptoms like eye irritation or lung changes, which may occur unpredictably during treatment.
Unlike chemotherapy, ADC-related side effects don't follow a fixed timeline, so consistent monitoring and patient communication are vital. Physicians rely heavily on patient-reported symptoms to make timely decisions. Managing new toxicities involves balancing treatment efficacy with early intervention to preserve both quality of life and long-term disease control.
